Aug. 25 at 10:17 PM
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:
$LABT ) has become a B2i Digital Featured Company, and the Sarasota, Florida clinical-stage biotechnology company is finalizing preparation of a Phase 2a proof-of-concept study of its lead candidate Nu-3. The company develops the Bisphosphocin® class, a novel group of fast-acting, broad-spectrum antimicrobials aimed at infectious diseases and antibiotic-resistant bacterial strains.
As a new B2i Digital Featured Company, a full company profile is coming soon to https://b2idigital.com/featured-companies
The program ahead of Nu-3 rests on a defined trial design, an appointed study chair, and a preclinical package the company reported in July:
• Roughly half of diabetic foot ulcers become infected, and 15% to 20% of those infected cases involve resistant pathogens, primarily MRSA
• The Phase 2a study will evaluate the safety and efficacy of topical Nu-3 gel at three concentrations, 2%, 5% and 10%, and is intended to support advancement into a larger Phase 2b study
• David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, accepted the position of Study Chair in June and will also serve as a Scientific Advisor on the iDFU program
• Nu-3 was well tolerated in an FDA-required preclinical safety study at dose levels substantially higher than those planned for Phase 2a, with very low systemic exposure
“Our focus is on bringing the Bisphosphocin® class into the clinic and generating the proof-of-concept data that will define its potential in infected diabetic foot ulcers,” said Kelvin Cooper, Ph.D., Chief Executive Officer of Lakewood-Amedex Biotherapeutics Inc.
Read the full release: https://www.newmediawire.com/news/lakewood-amedex-biotherapeutics-becomes-a-b2i-digital-featured-company-7088903
Bisphosphocin® compounds are small nucleotide derivatives proposed to act by destabilizing the bacterial cell membrane in a pH and concentration dependent way, typically within one minute of exposure. In laboratory profiling the company reports that Nu-3 did not induce resistance in a serial passage experiment and has shown broad-spectrum in vitro activity against bacteria carrying a diverse range of resistance mechanisms. The company reports an intellectual property estate of 72 issued patents and 29 pending applications, with principal filings running through 2038 and recent applications through 2044. Lakewood-Amedex began trading on the Nasdaq Capital Market under the symbol LABT following a direct listing in April 2026.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology Company developing a novel class of fast-acting, broad-spectrum antimicrobials, the Bisphosphocin® class, to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.
Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com.
B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. See the complete Disclosure at https://b2idigital.com/disclaimer.
